<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03207789</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 69605517.1.1001.5487</org_study_id>
    <nct_id>NCT03207789</nct_id>
  </id_info>
  <brief_title>T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients</brief_title>
  <acronym>Tcell-Brazil</acronym>
  <official_title>Prospective Collection of Data in Patients With T-cell Lymphomas Distributed in the Five Distinct Macro Regions of Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Estudos Multicentricos em Onco-Hematologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo de Estudos Multicentricos em Onco-Hematologia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The designed study follows up on the previous one by the international T-cell project (Bellei&#xD;
      et al,, 2012) and its purpose is to verify whether a prospective collection of data would&#xD;
      permit access to more accurate information permitting a better definition of prognosis and&#xD;
      investigation of more adequate treatment strategies for these neoplasms.&#xD;
&#xD;
      The analysis of patients distributed in all five macro regions of the country and a&#xD;
      comparison among them will provide a real picture of the disease in Brazil, limiting the bias&#xD;
      probably found in the previous projects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with diagnosis histologically confirmed T-cell or NK-cell lymphoma will be&#xD;
      registered in the study, despite of their planned treatment. Registration will be made&#xD;
      on-line on a key restricted accessible web-database after obtaining the informed consent&#xD;
      dated and signed by the patient. Every registered patient has as well to undergo a central&#xD;
      histopathology review by a panel of experts. The referring pathologist will collect and&#xD;
      review the patological material sent by the participating centers, without knowing the&#xD;
      clinical outcome of the patient. Validated cases have to be supplied of information regarding&#xD;
      treatment procedures and follow up updating for at least 5 years. The primary endpoint is the&#xD;
      overall survival and other endpoints such as event free survival; progression free survival,&#xD;
      complete and partial response rates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Descriptive analysis during the first year of T-cell Brazil Registry</measure>
    <time_frame>12 months of registring</time_frame>
    <description>Descriptive analysis and Overall survival</description>
  </primary_outcome>
  <enrollment type="Actual">500</enrollment>
  <condition>T-cell Lymphoma</condition>
  <condition>NK-Cell Lymphoma</condition>
  <condition>T-cell Lymphoma Adults</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with confirmed histologically diagnosis of T-cell or NH-cell lymphoma in any of 5&#xD;
        macro region of Brazil&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dated and signed informed consent;&#xD;
&#xD;
          -  T-cell or NK-cell diagnosis;&#xD;
&#xD;
          -  Tissue biopsies adequate for diagnosis and classification and available for&#xD;
             centralized review;&#xD;
&#xD;
          -  clinical, laboratory, image data available and registred in the website.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Eliana CM Miranda, M.Ed.; Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Grupo de Estudos Multicentricos em Onco-Hematologia</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

